GENOPTIX, INC.
CARLSBAD, CA

ABOUT GENOPTIX WHO WE ARE Genoptix is one of the largest hematopathology centers in the U.S. and is a leading clinical oncology laboratory specializing in hematology and solid tumors. Located in Carlsbad, California, with a staff of over 400, and occupying over 27,000 square feet of laboratory space, Genoptix’s modern facilities are well-suited to handle the large volume of samples that enters its doors each day. Genoptix provides personalized and comprehensive diagnostic services to hematologists, oncologists and pathologists, with a specialization in diagnosing cancers and disorders in bone marrow, blood, and lymph nodes, as well as in molecular testing of solid tumors. Through an integrated approach to case management, Genoptix delivers individualized, actionable results for each patient to help the referring physician make the best treatment decisions. At Genoptix, our vision is to be the world leader in specialized cancer diagnostics, providing definite answers that improve patients’ lives. OUR MISSION A productive tool for the At Genoptix, we make your life easier by developing tests and tools to help you manage your patients’ care. Let’s start with Genoptix Online, a powerful web portal that you can access 24/7 via your smart phone, tablet or computer to order Genoptix tests, check test status, review lab reports and access other helpful resource tools. Through Genoptix Online you can: Genoptix is a CAP-accredited and CLIA-certified oncology laboratory. MAKE GENOPTIX PART OF YOUR CANCER FIGHTING TEAM GENOPTIX TECHNOLOGIES Flow cytometry is a cornerstone diagnostic tool used in hematology screening. We use advanced instruments and laser technology to measure properties of cells and detect cancer cells in a sample of bone marrow, blood, or lymph node. After the sample is treated with fluorescent antibodies, it is scanned with a laser beam. If the antibodies are attached to the cells, they will give off light that helps quantify and identify the cell types. This most often provides a differential diagnosis for leukemia and lymphoma. Genoptix also uses this robust technology for assessment of clonal evolution, paroxysmal nocturnal hemoglobinuria (PNH) and minimal residual disease (MRD) for B-cell acute lymphocytic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). For many diseases, cytogenetics provides the next layer of information at the genomic level. Our cytogenetics lab performs karyotyping and fluorescence in situ hybridization (FISH) for disease markers and specific genetic and chromosomal anomalies. This is important because chromosomal analysis of leukemias, lymphomas and solid tumors may reveal abnormalities that will impact a patient’s diagnosis and treatment plan. Molecular testing may be used to help classify the disease and/or match the best treatment to the type of tumor. We use the most advanced genetic analysis and sequencing techniques including polymerase chain reaction (PCR) and next-generation sequencing (NGS). They are useful in the analysis of diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid lymphoma (CML), myeloproliferative neoplasms (MPN), colorectal cancer, central nervous system (CNS) cancer, lung cancer (NSCLC) and melanoma. Genoptix is one of the largest specialty oncology laboratories in the U.S. We provide community and hospital physicians with comprehensive testing solutions in hematology and solid tumors. Our company was built on providing the latest medical expertise with the most advanced technologies to help physicians make the right clinical decisions. Every day, we help patients and their families by providing the best information to help them on their journey in their fight against cancer. Genoptix is established in Southern California Genoptix becomes a publicly traded company on the NASDAQ exchange Genoptix is acquired by Novartis, Inc. Genoptix becomes the first reference laboratory to offer NGS commercially for oncology in the US Genoptix is acquired by Genesis Holdings, LLC and an experienced management team MOBILE READY: GENOPTIX ONLINE™ Genoptix is committed to providing solutions that simplify and streamline your workflow via our Genoptix Online web portal. You can now quickly and conveniently order and receive reports on hematology and solid tumor testing online, and gain access to other helpful resources enabling you to focus on what matters most—the patients you serve.